Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Saving the Vision of Children With Juvenile Rheumatoid Arthritis-Associated Uveitis

Article Abstract:

Uveitis potentially leading to blindness can develop in children with juvenile rheumatoid arthritis (JRA). Rheumatoid arthritis is an autoimmune inflammatory joint disease. Inflammation of the uvea, or vascular portion of the eye, may go undetected in children who do not notice slight changes in their vision. Ocular inflammation may develop in 89-24% of children with JRA, and 12% of children with uveitis may go blind. Topical corticosteroid drugs may be sufficient therapy, but oral corticosteroids and immunosuppressive drugs may be necessary. Comprehensive eye examination, including slit-lamp inspection, should be performed regularly in children with JRA.

Author: Nguyen, Quan Dong, Foster, C. Stephen
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
Care and treatment, Causes of, Complications and side effects, Uveitis, Rheumatoid arthritis in children, Juvenile rheumatoid arthritis, Ocular manifestations of general diseases, Eye manifestations, Children, Blind, Blind children

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Prospects for Autoimmune Disease - Research Advances in Rheumatoid Arthritis

Article Abstract:

The treatment of rheumatoid arthritis has been advanced by the development of drugs that can actually modify the course of the disease rather than just treat the pain. One such treatment is drugs that block the activity of tumor necrosis factor, which is a naturally occurring inflammatory substance in the body.

Author: Koopman, William J.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Research, Rheumatoid arthritis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial

Article Abstract:

The drug methotrexate may not benefit people who have autoimmune inner ear disease, according to a study of 67 patients. This ear disease causes hearing loss that may be reversible if it is treated promptly. Many patients are treated with corticosteroid drugs.

Author: Niparko, John K., Espeland, Mark A., Brookhouser, Patrick E., Weisman, Michael H., Harris, Jeffrey P., Derebery, Jennifer M., Gantz, Bruce J., Gulya, A. Julianna, Hammerschlag, Paul E., Hannley, Maureen, Hughes, Gordon B., Moscicki, Richard, Nelson, Ralph A., Rauch, Steven D., Telian, Steven A.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Evaluation, Drug therapy, Autoimmune diseases, Hearing loss, Methotrexate

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Similar abstracts:
  • Abstracts: Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis. part 2 Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis
  • Abstracts: Circadian rhythm of serum cytidine deaminase in patients with rheumatoid arthritis during rest and exercise. Effect of circulating immune complexes on the binding of rheumatoid factor to histones
  • Abstracts: Urinary tract disorders in patients with chronic granulomatous disease. Hyperparathyroid and hypoparathyroid disorders
  • Abstracts: Regulation of cell volume in health and disease. Human cloning and the challenge of regulation. The FDA, regulation, and the risk of stroke
  • Abstracts: Early detection: the next steps. User acceptability and feasibility of self-testing with HIV rapid tests. HIV testing from a community perspective
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.